BioPorto Announces Q3 2019 Report

    NEXT STORY
    Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
    PREV STORY
    Molecular Templates, Inc. Announces Proposed Public Equity Offering
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu

    Baloxavir marboxil - an investigational oral, single-dose antiviral - is the first flu medicine ...

    author_avatar
    NASDAQ Market News

    Vystar Acquires Assets of NHS Holdings

    author_avatar
    NASDAQ Market News

    Industry Veteran Maureen Franco’s Arrival at LifeSci Public Relations Highlights Firm’s Growth Trajectory

    author_avatar
    NASDAQ Market News